Regeneron Pharmaceuticals Inc. (REGN)


Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Beginner level


Long-term Activity Ratios (Summary)

Regeneron Pharmaceuticals Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Net fixed asset turnover 2.75 2.70 2.65 2.61 2.52 2.52 2.53 2.49 2.43 2.32 2.19 2.33 2.53 2.62 2.66 2.57 2.58 2.56 2.76 2.89
Total asset turnover 0.55 0.55 0.54 0.57 0.59 0.62 0.65 0.67 0.63 0.65 0.64 0.70 0.69 0.75 0.75 0.73 0.73 0.75 0.73 0.73
Equity turnover 0.73 0.74 0.73 0.77 0.81 0.86 0.92 0.96 0.91 0.95 1.02 1.09 1.05 1.14 1.18 1.12 1.16 1.02 1.03 1.11

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Regeneron Pharmaceuticals Inc.’s net fixed asset turnover ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Regeneron Pharmaceuticals Inc.’s total asset turnover ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Regeneron Pharmaceuticals Inc.’s equity turnover ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.

Net Fixed Asset Turnover

Regeneron Pharmaceuticals Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Revenues 2,048,400  1,933,700  1,711,800  1,927,797  1,663,496  1,608,022  1,511,485  1,582,447  1,500,673  1,470,116  1,318,991  1,226,827  1,220,122  1,212,629  1,200,849  1,098,077  1,137,422  998,617  869,612  802,329  725,788  665,700  625,740 
Property, plant, and equipment, net 2,771,400  2,676,600  2,612,800  2,575,800  2,524,446  2,461,614  2,394,727  2,358,605  2,274,529  2,261,702  2,277,029  2,083,421  1,872,167  1,772,923  1,666,391  1,594,120  1,475,123  1,326,112  1,110,597  974,309  818,967  707,321  600,864 
Long-term Activity Ratio
Net fixed asset turnover1 2.75 2.70 2.65 2.61 2.52 2.52 2.53 2.49 2.43 2.32 2.19 2.33 2.53 2.62 2.66 2.57 2.58 2.56 2.76 2.89
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories 4.01 3.95 4.03 4.04 4.08 3.98 3.71 3.60 3.48 3.24 3.07 3.66 3.61 3.53 3.49 3.56 3.55 3.57 3.58 3.41
AbbVie Inc. 11.36 11.33 11.42 11.36 10.91 11.10 10.47 10.07 10.11 10.05 10.04 9.85 9.57 9.46 9.16 8.91 8.61 8.34 8.41 8.03
Allergan PLC 8.52 8.61 8.82 8.83 9.13 9.17 9.06 8.93 8.59 8.61 8.89 9.04 8.54 8.89 9.93 9.58 10.49 5.62 4.64 8.19
Amgen Inc. 4.55 4.58 4.59 4.54 4.51 4.48 4.44 4.37 4.45 4.41 4.41 4.41 4.39 4.41 4.36 4.27 4.17 3.98 3.87 3.70
Biogen Inc. 4.54 4.57 4.58 3.74 3.74 3.78 3.78 3.86 3.95 4.14 4.42 4.58 4.78 4.88 4.84 4.92 5.21 5.60 5.82 5.50
Bristol-Myers Squibb Co. 5.00 4.92 4.67 4.49 4.33 4.25 4.16 4.15 4.10 4.09 3.98 3.90 3.86 3.83 3.80 3.75 3.89 3.75 3.73 3.59
Eli Lilly & Co. 2.90 2.96 3.08 2.75 2.75 2.72 2.61 2.59 2.61 2.56 2.56 2.57 2.53 2.55 2.51 2.48 2.44 2.45 2.46 2.46
Gilead Sciences Inc. 5.03 5.16 5.31 5.41 5.76 6.23 7.11 7.79 8.72 9.31 9.80 10.45 11.48 12.29 13.34 14.13 14.45 15.12 15.30 14.62
Johnson & Johnson 4.79 4.72 4.80 4.79 4.89 4.85 4.62 4.50 4.47 4.41 4.46 4.52 4.45 4.44 4.40 4.41 4.53 4.61 4.79 4.61
Merck & Co. Inc. 3.22 3.20 3.19 3.18 3.27 3.27 3.24 3.23 3.27 3.31 3.32 3.31 3.32 3.29 3.19 3.16 3.19 3.19 3.21 3.22
Pfizer Inc. 3.87 3.97 4.00 4.01 3.80 3.83 3.77 3.79 3.89 3.91 3.97 3.97 4.01 3.84 3.75 3.55 3.50 4.22 4.26 4.22

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

1 Q3 2019 Calculation
Net fixed asset turnover = (RevenuesQ3 2019 + RevenuesQ2 2019 + RevenuesQ1 2019 + RevenuesQ4 2018) ÷ Property, plant, and equipment, net
= (2,048,400 + 1,933,700 + 1,711,800 + 1,927,797) ÷ 2,771,400 = 2.75

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Regeneron Pharmaceuticals Inc.’s net fixed asset turnover ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Total Asset Turnover

Regeneron Pharmaceuticals Inc., total asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Revenues 2,048,400  1,933,700  1,711,800  1,927,797  1,663,496  1,608,022  1,511,485  1,582,447  1,500,673  1,470,116  1,318,991  1,226,827  1,220,122  1,212,629  1,200,849  1,098,077  1,137,422  998,617  869,612  802,329  725,788  665,700  625,740 
Total assets 13,939,300  13,173,600  12,854,800  11,734,500  10,805,613  9,951,980  9,372,696  8,764,286  8,701,215  8,106,373  7,817,365  6,973,466  6,828,019  6,204,906  5,904,460  5,609,132  5,182,915  4,526,970  4,198,573  3,871,827  3,739,419  3,456,078  3,260,396 
Long-term Activity Ratio
Total asset turnover1 0.55 0.55 0.54 0.57 0.59 0.62 0.65 0.67 0.63 0.65 0.64 0.70 0.69 0.75 0.75 0.73 0.73 0.75 0.73 0.73
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories 0.46 0.45 0.45 0.46 0.42 0.43 0.40 0.36 0.35 0.33 0.31 0.40 0.52 0.52 0.51 0.49 0.49 0.46 0.47 0.49
AbbVie Inc. 0.55 0.57 0.58 0.55 0.49 0.50 0.43 0.40 0.40 0.40 0.40 0.39 0.38 0.37 0.44 0.43 0.40 0.39 0.77 0.72
Allergan PLC 0.17 0.16 0.16 0.16 0.15 0.15 0.14 0.13 0.13 0.12 0.12 0.11 0.09 0.10 0.12 0.11 0.12 0.12 0.09 0.25
Amgen Inc. 0.37 0.38 0.35 0.34 0.33 0.33 0.31 0.27 0.27 0.28 0.28 0.28 0.28 0.29 0.28 0.29 0.29 0.28 0.29 0.28
Biogen Inc. 0.52 0.54 0.52 0.53 0.52 0.54 0.48 0.52 0.51 0.54 0.54 0.50 0.52 0.52 0.53 0.55 0.51 0.61 0.67 0.68
Bristol-Myers Squibb Co. 0.42 0.43 0.67 0.64 0.65 0.66 0.64 0.62 0.61 0.61 0.61 0.58 0.55 0.54 0.53 0.52 0.52 0.51 0.48 0.47
Eli Lilly & Co. 0.60 0.60 0.63 0.56 0.54 0.56 0.53 0.51 0.52 0.54 0.57 0.55 0.55 0.56 0.58 0.56 0.54 0.54 0.55 0.53
Gilead Sciences Inc. 0.37 0.35 0.35 0.34 0.34 0.35 0.37 0.37 0.42 0.47 0.50 0.53 0.55 0.64 0.68 0.62 0.61 0.73 0.70 0.71
Johnson & Johnson 0.53 0.52 0.54 0.53 0.52 0.52 0.50 0.49 0.48 0.47 0.50 0.51 0.51 0.51 0.52 0.53 0.53 0.54 0.57 0.57
Merck & Co. Inc. 0.55 0.53 0.52 0.51 0.49 0.49 0.47 0.46 0.43 0.43 0.41 0.42 0.41 0.41 0.40 0.39 0.39 0.39 0.38 0.43
Pfizer Inc. 0.31 0.34 0.35 0.34 0.32 0.32 0.32 0.31 0.30 0.31 0.31 0.31 0.30 0.31 0.31 0.29 0.28 0.30 0.31 0.29

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

1 Q3 2019 Calculation
Total asset turnover = (RevenuesQ3 2019 + RevenuesQ2 2019 + RevenuesQ1 2019 + RevenuesQ4 2018) ÷ Total assets
= (2,048,400 + 1,933,700 + 1,711,800 + 1,927,797) ÷ 13,939,300 = 0.55

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Regeneron Pharmaceuticals Inc.’s total asset turnover ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019.

Equity Turnover

Regeneron Pharmaceuticals Inc., equity turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Revenues 2,048,400  1,933,700  1,711,800  1,927,797  1,663,496  1,608,022  1,511,485  1,582,447  1,500,673  1,470,116  1,318,991  1,226,827  1,220,122  1,212,629  1,200,849  1,098,077  1,137,422  998,617  869,612  802,329  725,788  665,700  625,740 
Stockholders’ equity 10,504,400  9,755,900  9,444,700  8,757,300  7,868,300  7,186,426  6,567,644  6,144,078  6,051,593  5,520,738  4,866,021  4,449,245  4,491,247  4,076,506  3,765,082  3,654,837  3,296,867  3,338,458  2,971,430  2,542,325  2,551,788  2,368,842  2,211,248 
Long-term Activity Ratio
Equity turnover1 0.73 0.74 0.73 0.77 0.81 0.86 0.92 0.96 0.91 0.95 1.02 1.09 1.05 1.14 1.18 1.12 1.16 1.02 1.03 1.11
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories 0.99 0.98 0.99 1.00 0.99 0.97 0.91 0.89 0.78 0.75 0.71 1.02 1.00 0.99 0.98 0.96 0.97 0.89 0.93 0.94
AbbVie Inc. 8.33 5.54 4.08 4.44 5.25 5.53 3.90 4.39 5.12 5.79 4.51 3.81 14.84 11.46
Allergan PLC 0.27 0.26 0.26 0.24 0.23 0.23 0.22 0.22 0.22 0.20 0.20 0.19 0.15 0.18 0.21 0.20 0.21 0.22 0.18 0.46
Amgen Inc. 2.04 2.07 2.07 1.80 1.54 1.48 1.40 0.86 0.68 0.69 0.71 0.73 0.70 0.72 0.74 0.75 0.74 0.73 0.75 0.75
Biogen Inc. 1.02 1.09 1.00 1.03 0.96 1.05 0.90 0.97 0.92 1.01 1.00 0.94 0.94 0.99 1.06 1.15 1.00 0.82 0.87 0.90
Bristol-Myers Squibb Co. 1.37 1.49 1.53 1.61 1.62 1.75 1.64 1.77 1.39 1.38 1.38 1.20 1.18 1.18 1.18 1.16 1.10 1.08 1.04 1.07
Eli Lilly & Co. 6.69 8.35 9.66 2.50 1.86 2.07 1.61 1.97 1.51 1.56 1.54 1.52 1.34 1.41 1.34 1.37 1.29 1.34 1.31 1.28
Gilead Sciences Inc. 1.07 0.97 1.00 1.01 0.96 1.05 1.18 1.26 1.09 1.24 1.40 1.59 1.85 2.06 2.42 1.73 1.78 1.76 1.57 1.59
Johnson & Johnson 1.40 1.34 1.38 1.37 1.26 1.28 1.24 1.27 1.01 1.01 1.03 1.02 0.98 0.98 0.97 0.98 0.99 1.01 1.08 1.07
Merck & Co. Inc. 1.71 1.61 1.56 1.58 1.29 1.27 1.21 1.17 1.04 1.01 1.00 0.99 0.91 0.91 0.90 0.88 0.87 0.87 0.87 0.87
Pfizer Inc. 0.81 0.90 0.92 0.85 0.75 0.76 0.72 0.74 0.86 0.90 0.90 0.89 0.84 0.83 0.81 0.75 0.72 0.72 0.73 0.70

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

1 Q3 2019 Calculation
Equity turnover = (RevenuesQ3 2019 + RevenuesQ2 2019 + RevenuesQ1 2019 + RevenuesQ4 2018) ÷ Stockholders’ equity
= (2,048,400 + 1,933,700 + 1,711,800 + 1,927,797) ÷ 10,504,400 = 0.73

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Regeneron Pharmaceuticals Inc.’s equity turnover ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.